Michael Mildner

Prof. Michael Mildner

Department of Dermatology, Medical University of Vienna, Vienna, Austria
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ARAna Rakita
Ana Rakita
NNNenad Nikolić
Nenad Nikolić
Michael MildnerMichael Mildner
Michael Mildner
JMJohannes Matiasek
Johannes Matiasek
AEAdelheid Elbe-Bürger
Adelheid Elbe-Bürger
A large body of literature is available on wound healing in humans. Nonetheless, a standardizedex vivowound model without disruption of the dermal compartment has not been put forward with compelling justification. Here, we present a novel wound model based on application of negative pressure and its effects for epidermal regeneration and immune cell behaviour. Importantly, the basement membrane remained intact after blister roof removal and keratinocytes were absent in the wounded area. Upon six days of culture, the wound was covered with one to three-cell thick K14+Ki67+keratinocyte layers, indicating that proliferation and migration were involved in wound closure. After eight to twelve days, a multi-layered epidermis was formed expressing epidermal differentiation markers (K10, filaggrin, DSG-1, CDSN). Investigations about immune cell-specific manners revealed more T cells in the blister roof epidermis compared to normal epidermis. We identified several cell populations in blister roof epidermis and suction blister fluid that are absent in normal epidermis which correlated with their decrease in the dermis, indicating a dermal efflux upon negative pressure. Together, our model recapitulates the main features of epithelial wound regeneration, and can be applied for testing wound healing therapies and investigating underlying mechanisms.

16 March 2010 in Aging Cell
Verified
Journal Article
Open access
PDF file
MHMatthias Hackl
Matthias Hackl
SBStefan Brunner
Stefan Brunner
KFKlaus Fortschegger
Klaus Fortschegger
CSCarina Schreiner
Carina Schreiner
LMLucia Micutkova
Lucia Micutkova
JGJohannes Grillari
Johannes Grillari
Summary: Aging is a multifactorial process where deterioration of body functions is driven by stochastic damage while counteracted by distinct genetically encoded repair systems. To better understand the genetic component of aging, many studies have addressed the gene and protein expression profiles of various aging model systems engaging different organisms from yeast to human. The recently identified small non‐coding miRNAs are potent post‐transcriptional regulators that can modify the expression of up to several hundred target genes per single miRNA, similar to transcription factors. Increasing evidence shows that miRNAs contribute to the regulation of most if not all important physiological processes, including aging. However, so far the contribution of miRNAs to age‐related and senescence‐related changes in gene expression remains elusive. To address this question, we have selected four replicative cell aging models including endothelial cells, replicated CD8+ T cells, renal proximal tubular epithelial cells, and skin fibroblasts. Further included were three organismal aging models including foreskin, mesenchymal stem cells, and CD8+ T cell populations from old and young donors. Using locked nucleic acid‐based miRNA microarrays, we identified four commonly regulated miRNAs, miR‐17 down‐regulated in all seven; miR‐19b and miR‐20a, down‐regulated in six models; and miR‐106a down‐regulated in five models. Decrease in these miRNAs correlated with increased transcript levels of some established target genes, especially the cdk inhibitor p21/CDKN1A. These results establish miRNAs as novel markers of cell aging in humans.

1 September 2010 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
Michael MildnerMichael Mildner
Michael Mildner
JJJiang Jin
Jiang Jin
LELeopold Eckhart
Leopold Eckhart
SKSanja Kezic
Sanja Kezic
FGFlorian Gruber
Florian Gruber
ETErwin Tschachler
Erwin Tschachler

1 November 2020 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
TRThomas B. Rojahn
Thomas B. Rojahn
VVVera Vorstandlechner
Vera Vorstandlechner
TKThomas Krausgruber
Thomas Krausgruber
WBWolfgang M. Bauer
Wolfgang M. Bauer
NANatalia Alkon
Natalia Alkon
PBPatrick M. Brunner
Patrick M. Brunner

1 May 2011 in The American Journal of Pathology
Verified
Journal Article
Closed access
RGRobert Gruber
Robert Gruber
PEPeter M. Elias
Peter M. Elias
DCDebra Crumrine
Debra Crumrine
TLTzu-Kai Lin
Tzu-Kai Lin
JBJohanna M. Brandner
Johanna M. Brandner
MSMatthias Schmuth
Matthias Schmuth

8 January 2021 in Science Immunology
Verified
Journal Article
Closed access
PDF file
CBChristine Bangert
Christine Bangert
KRKatharina Rindler
Katharina Rindler
TKThomas Krausgruber
Thomas Krausgruber
NANatalia Alkon
Natalia Alkon
FTFelix M. Thaler
Felix M. Thaler
PBPatrick M. Brunner
Patrick M. Brunner
Therapeutic options for autoimmune diseases typically consist of broad and targeted immunosuppressive agents. However, sustained clinical benefit is rarely achieved, as the disease phenotype usually returns after cessation of treatment. To better understand tissue-resident immune memory in human disease, we investigated patients with atopic dermatitis (AD) who underwent short-term or long-term treatment with the IL-4Rα blocker dupilumab. Using multi-omics profiling with single-cell RNA sequencing and multiplex proteomics, we found significant decreases in overall skin immune cell counts and normalization of transcriptomic dysregulation in keratinocytes consistent with clearance of disease. However, we identified specific immune cell populations that persisted for up to a year after clinical remission while being absent from healthy controls. These populations included LAMP3+ CCL22+ mature dendritic cells, CRTH2+ CD161+ T helper (“TH2A”) cells, and CRTAM+ cytotoxic T cells, which expressed high levels of CCL17 (dendritic cells) and IL13 (T cells). TH2A cells showed a characteristic cytokine receptor constellation with IL17RB, IL1RL1 (ST2), and CRLF2 expression, suggesting that these cells are key responders to the AD-typical epidermal alarmins IL-25, IL-33, and TSLP, respectively. We thus identified disease-linked immune cell populations in resolved AD indicative of a persisting disease memory, facilitating a rapid response system of epidermal-dermal cross-talk between keratinocytes, dendritic cells, and T cells. This observation may help to explain the disease recurrence upon termination of immunosuppressive treatments in AD, and it identifies potential disease memory–linked cell types that may be targeted to achieve a more sustained therapeutic response.